Organon Is Ready To Launch And Makes The Case To Investors
Established Products Will Account For The Majority Of Revenues
Executive Summary
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
You may also be interested in...
Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
Organon Is Serious About Building A Women's Health Company, Deal By Deal
CEO Kevin Ali talked to Scrip about his plans for Organon, ahead of the spinout from Merck & Co. Women's health will be the top priority.
What’s Next? Five Things To Look Out For In June
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.